Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-04-13

AUTHORS

M Lübbert, H Bertz, B Rüter, R Marks, R Claus, R Wäsch, J Finke

ABSTRACT

Novel, non-intensive treatment options in older MDS/AML patients planned for allografting, with the goal of down-staging the underlying disease and bridging time to transplantation, are presently being developed. 5-azacytidine and decitabine (DAC) are of particular interest, as they can be given repetitively, with very limited non-hematologic toxicity and result in responses both in MDS and AML even at low doses. We describe 15 consecutive patients (median age 69 years, range 60–75 years) with MDS (n=10) or AML (n=5) who all received first-line treatment with DAC and subsequent allografting (from sibling donor in four patients, unrelated donor in 11) after reduced-intensity conditioning with the FBM regimen. Successful engraftment was attained in 14/15 patients, all of whom achieved a CR, with a median duration of 5 months (range 1+ to 51+). Six of these 14 patients are alive (4 with complete donor chimerism), 8 have died either from relapse (n=4) or treatment-related complications while in CR (n=4). We conclude that allografting after low-dose DAC and subsequent conditioning with FBM is feasible, with no unexpected toxicities and appears as a valid alternative to standard chemotherapy (‘InDACtion instead of induction’) in elderly patients with MDS/AML. More... »

PAGES

585-588

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bmt.2009.64

DOI

http://dx.doi.org/10.1038/bmt.2009.64

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1045435788

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19363531


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azacitidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Decitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation Conditioning", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "L\u00fcbbert", 
        "givenName": "M", 
        "id": "sg:person.01153663723.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bertz", 
        "givenName": "H", 
        "id": "sg:person.01356464223.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356464223.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "2Current address: Merck Darmstadt, Darmstadt, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
            "2Current address: Merck Darmstadt, Darmstadt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "R\u00fcter", 
        "givenName": "B", 
        "id": "sg:person.0750355777.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750355777.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marks", 
        "givenName": "R", 
        "id": "sg:person.01201522565.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201522565.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "3Current address: Department of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
            "3Current address: Department of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Claus", 
        "givenName": "R", 
        "id": "sg:person.0727645451.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727645451.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "W\u00e4sch", 
        "givenName": "R", 
        "id": "sg:person.01151333006.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151333006.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Finke", 
        "givenName": "J", 
        "id": "sg:person.01341317720.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341317720.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.leu.2404796", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003666698", 
          "https://doi.org/10.1038/sj.leu.2404796"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-04-13", 
    "datePublishedReg": "2009-04-13", 
    "description": "Novel, non-intensive treatment options in older MDS/AML patients planned for allografting, with the goal of down-staging the underlying disease and bridging time to transplantation, are presently being developed. 5-azacytidine and decitabine (DAC) are of particular interest, as they can be given repetitively, with very limited non-hematologic toxicity and result in responses both in MDS and AML even at low doses. We describe 15 consecutive patients (median age 69 years, range 60\u201375 years) with MDS (n=10) or AML (n=5) who all received first-line treatment with DAC and subsequent allografting (from sibling donor in four patients, unrelated donor in 11) after reduced-intensity conditioning with the FBM regimen. Successful engraftment was attained in 14/15 patients, all of whom achieved a CR, with a median duration of 5 months (range 1+ to 51+). Six of these 14 patients are alive (4 with complete donor chimerism), 8 have died either from relapse (n=4) or treatment-related complications while in CR (n=4). We conclude that allografting after low-dose DAC and subsequent conditioning with FBM is feasible, with no unexpected toxicities and appears as a valid alternative to standard chemotherapy (\u2018InDACtion instead of induction\u2019) in elderly patients with MDS/AML.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bmt.2009.64", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096890", 
        "issn": [
          "0268-3369", 
          "1476-5365"
        ], 
        "name": "Bone Marrow Transplantation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "MDS/AML patients", 
      "AML patients", 
      "non-hematologic toxicities", 
      "treatment-related complications", 
      "first-line treatment", 
      "reduced-intensity conditioning", 
      "MDS/AML", 
      "non-intensive treatment", 
      "low-dose DAC", 
      "median duration", 
      "standard chemotherapy", 
      "elderly patients", 
      "consecutive patients", 
      "treatment options", 
      "successful engraftment", 
      "unexpected toxicities", 
      "patients", 
      "low doses", 
      "AML", 
      "subsequent conditioning", 
      "valid alternative", 
      "treatment", 
      "toxicity", 
      "MDS", 
      "regimen", 
      "complications", 
      "chemotherapy", 
      "transplantation", 
      "allografting", 
      "relapse", 
      "engraftment", 
      "decitabine", 
      "disease", 
      "doses", 
      "months", 
      "SCT", 
      "duration", 
      "conditioning", 
      "options", 
      "response", 
      "particular interest", 
      "FBM", 
      "alternative", 
      "time", 
      "goal", 
      "Cr", 
      "interest", 
      "DAC"
    ], 
    "name": "Non-intensive treatment with low-dose 5-aza-2\u2032-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients", 
    "pagination": "585-588", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1045435788"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bmt.2009.64"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19363531"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bmt.2009.64", 
      "https://app.dimensions.ai/details/publication/pub.1045435788"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_497.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bmt.2009.64"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bmt.2009.64'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bmt.2009.64'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bmt.2009.64'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bmt.2009.64'


 

This table displays all metadata directly associated to this object as RDF triples.

231 TRIPLES      21 PREDICATES      91 URIs      82 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bmt.2009.64 schema:about N248384faa562495f91c038ac7d7cc120
2 N3bb32ed361ac49c195c79e7f9c83bdba
3 N5dc38aab3fef46989773b20b81bc4870
4 N6b62ed9d37c547cda1ac7ef244926b12
5 N7065458801b14f9d96e0f6273b975d40
6 N72ba38028cff4766b37f0df6f532dd92
7 N72cf38b378eb45df93e0e97440c338da
8 N7d74e77f2cc74d2b89219636d3a05b67
9 N8edd73595b8c428da38f6c54870c0fde
10 N94619fd2bae24a1387edc1106fddbf86
11 Na4b94ca390314a21a92fac150926d884
12 Nad321cbeda0b49e08528caab6e119eb1
13 Nba4b98c82bc3442bb92958e90952dff2
14 Nbb4cf9f7d37141fdae97effe3477caf6
15 Nc7b29b992b0e44de8e7c96d74d36cd7a
16 Ndc47399457a645949fbc8ffb405a8f25
17 Nea597d8bd7434731b397067369fa90f2
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author Nb50a933609ce424a92f6e7cd7f8ad138
21 schema:citation sg:pub.10.1038/sj.leu.2404796
22 schema:datePublished 2009-04-13
23 schema:datePublishedReg 2009-04-13
24 schema:description Novel, non-intensive treatment options in older MDS/AML patients planned for allografting, with the goal of down-staging the underlying disease and bridging time to transplantation, are presently being developed. 5-azacytidine and decitabine (DAC) are of particular interest, as they can be given repetitively, with very limited non-hematologic toxicity and result in responses both in MDS and AML even at low doses. We describe 15 consecutive patients (median age 69 years, range 60–75 years) with MDS (n=10) or AML (n=5) who all received first-line treatment with DAC and subsequent allografting (from sibling donor in four patients, unrelated donor in 11) after reduced-intensity conditioning with the FBM regimen. Successful engraftment was attained in 14/15 patients, all of whom achieved a CR, with a median duration of 5 months (range 1+ to 51+). Six of these 14 patients are alive (4 with complete donor chimerism), 8 have died either from relapse (n=4) or treatment-related complications while in CR (n=4). We conclude that allografting after low-dose DAC and subsequent conditioning with FBM is feasible, with no unexpected toxicities and appears as a valid alternative to standard chemotherapy (‘InDACtion instead of induction’) in elderly patients with MDS/AML.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf N0938d524001746768cde30049227e6a6
28 Nc4bc2aff0df641f195284ab9a57537b5
29 sg:journal.1096890
30 schema:keywords AML
31 AML patients
32 Cr
33 DAC
34 FBM
35 MDS
36 MDS/AML
37 MDS/AML patients
38 SCT
39 allografting
40 alternative
41 chemotherapy
42 complications
43 conditioning
44 consecutive patients
45 decitabine
46 disease
47 doses
48 duration
49 elderly patients
50 engraftment
51 first-line treatment
52 goal
53 interest
54 low doses
55 low-dose DAC
56 median duration
57 months
58 non-hematologic toxicities
59 non-intensive treatment
60 options
61 particular interest
62 patients
63 reduced-intensity conditioning
64 regimen
65 relapse
66 response
67 standard chemotherapy
68 subsequent conditioning
69 successful engraftment
70 time
71 toxicity
72 transplantation
73 treatment
74 treatment options
75 treatment-related complications
76 unexpected toxicities
77 valid alternative
78 schema:name Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients
79 schema:pagination 585-588
80 schema:productId N41f881b3704b473ea5ebc65f155f6756
81 N81f3b90ba72a4c9e8b24021f060305a4
82 Nfc6d139d7fe04001991942fef3eda618
83 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045435788
84 https://doi.org/10.1038/bmt.2009.64
85 schema:sdDatePublished 2022-11-24T20:54
86 schema:sdLicense https://scigraph.springernature.com/explorer/license/
87 schema:sdPublisher Nbbcd7005d82c4048a2f3522adcbdceec
88 schema:url https://doi.org/10.1038/bmt.2009.64
89 sgo:license sg:explorer/license/
90 sgo:sdDataset articles
91 rdf:type schema:ScholarlyArticle
92 N0338ab913ab54f3695317aa85cfaea36 rdf:first sg:person.0727645451.47
93 rdf:rest N17e0252019ba414d97087bf4962de3c8
94 N0938d524001746768cde30049227e6a6 schema:issueNumber 9
95 rdf:type schema:PublicationIssue
96 N17e0252019ba414d97087bf4962de3c8 rdf:first sg:person.01151333006.25
97 rdf:rest N60c1714388a54fcb8d3c10f353be23e0
98 N1afab14e4b914c95a34eeadf897951d6 rdf:first sg:person.0750355777.66
99 rdf:rest N5cf43ce823fd4302bb3ba17bfabdf50d
100 N248384faa562495f91c038ac7d7cc120 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Disease Progression
102 rdf:type schema:DefinedTerm
103 N3bb32ed361ac49c195c79e7f9c83bdba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Antimetabolites, Antineoplastic
105 rdf:type schema:DefinedTerm
106 N41f881b3704b473ea5ebc65f155f6756 schema:name doi
107 schema:value 10.1038/bmt.2009.64
108 rdf:type schema:PropertyValue
109 N5cf43ce823fd4302bb3ba17bfabdf50d rdf:first sg:person.01201522565.95
110 rdf:rest N0338ab913ab54f3695317aa85cfaea36
111 N5dc38aab3fef46989773b20b81bc4870 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Hematopoietic Stem Cell Transplantation
113 rdf:type schema:DefinedTerm
114 N60c1714388a54fcb8d3c10f353be23e0 rdf:first sg:person.01341317720.21
115 rdf:rest rdf:nil
116 N6b62ed9d37c547cda1ac7ef244926b12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Risk Factors
118 rdf:type schema:DefinedTerm
119 N7065458801b14f9d96e0f6273b975d40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Leukemia, Myeloid, Acute
121 rdf:type schema:DefinedTerm
122 N72ba38028cff4766b37f0df6f532dd92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Survival Rate
124 rdf:type schema:DefinedTerm
125 N72cf38b378eb45df93e0e97440c338da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Decitabine
127 rdf:type schema:DefinedTerm
128 N7d74e77f2cc74d2b89219636d3a05b67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Azacitidine
130 rdf:type schema:DefinedTerm
131 N81f3b90ba72a4c9e8b24021f060305a4 schema:name dimensions_id
132 schema:value pub.1045435788
133 rdf:type schema:PropertyValue
134 N8edd73595b8c428da38f6c54870c0fde schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Aged
136 rdf:type schema:DefinedTerm
137 N94619fd2bae24a1387edc1106fddbf86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Dose-Response Relationship, Drug
139 rdf:type schema:DefinedTerm
140 Na4b94ca390314a21a92fac150926d884 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Myelodysplastic Syndromes
142 rdf:type schema:DefinedTerm
143 Nad321cbeda0b49e08528caab6e119eb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 Nb50a933609ce424a92f6e7cd7f8ad138 rdf:first sg:person.01153663723.53
147 rdf:rest Nd2c1a9ec224b4470961aedae0dab65ca
148 Nba4b98c82bc3442bb92958e90952dff2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Female
150 rdf:type schema:DefinedTerm
151 Nbb4cf9f7d37141fdae97effe3477caf6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Combined Modality Therapy
153 rdf:type schema:DefinedTerm
154 Nbbcd7005d82c4048a2f3522adcbdceec schema:name Springer Nature - SN SciGraph project
155 rdf:type schema:Organization
156 Nc4bc2aff0df641f195284ab9a57537b5 schema:volumeNumber 44
157 rdf:type schema:PublicationVolume
158 Nc7b29b992b0e44de8e7c96d74d36cd7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Transplantation Conditioning
160 rdf:type schema:DefinedTerm
161 Nd2c1a9ec224b4470961aedae0dab65ca rdf:first sg:person.01356464223.06
162 rdf:rest N1afab14e4b914c95a34eeadf897951d6
163 Ndc47399457a645949fbc8ffb405a8f25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Middle Aged
165 rdf:type schema:DefinedTerm
166 Nea597d8bd7434731b397067369fa90f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Male
168 rdf:type schema:DefinedTerm
169 Nfc6d139d7fe04001991942fef3eda618 schema:name pubmed_id
170 schema:value 19363531
171 rdf:type schema:PropertyValue
172 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
173 schema:name Medical and Health Sciences
174 rdf:type schema:DefinedTerm
175 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
176 schema:name Clinical Sciences
177 rdf:type schema:DefinedTerm
178 sg:journal.1096890 schema:issn 0268-3369
179 1476-5365
180 schema:name Bone Marrow Transplantation
181 schema:publisher Springer Nature
182 rdf:type schema:Periodical
183 sg:person.01151333006.25 schema:affiliation grid-institutes:grid.7708.8
184 schema:familyName Wäsch
185 schema:givenName R
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151333006.25
187 rdf:type schema:Person
188 sg:person.01153663723.53 schema:affiliation grid-institutes:grid.7708.8
189 schema:familyName Lübbert
190 schema:givenName M
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53
192 rdf:type schema:Person
193 sg:person.01201522565.95 schema:affiliation grid-institutes:grid.7708.8
194 schema:familyName Marks
195 schema:givenName R
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201522565.95
197 rdf:type schema:Person
198 sg:person.01341317720.21 schema:affiliation grid-institutes:grid.7708.8
199 schema:familyName Finke
200 schema:givenName J
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341317720.21
202 rdf:type schema:Person
203 sg:person.01356464223.06 schema:affiliation grid-institutes:grid.7708.8
204 schema:familyName Bertz
205 schema:givenName H
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356464223.06
207 rdf:type schema:Person
208 sg:person.0727645451.47 schema:affiliation grid-institutes:grid.7497.d
209 schema:familyName Claus
210 schema:givenName R
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727645451.47
212 rdf:type schema:Person
213 sg:person.0750355777.66 schema:affiliation grid-institutes:None
214 schema:familyName Rüter
215 schema:givenName B
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750355777.66
217 rdf:type schema:Person
218 sg:pub.10.1038/sj.leu.2404796 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003666698
219 https://doi.org/10.1038/sj.leu.2404796
220 rdf:type schema:CreativeWork
221 grid-institutes:None schema:alternateName 2Current address: Merck Darmstadt, Darmstadt, Germany
222 schema:name 2Current address: Merck Darmstadt, Darmstadt, Germany
223 Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
224 rdf:type schema:Organization
225 grid-institutes:grid.7497.d schema:alternateName 3Current address: Department of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany
226 schema:name 3Current address: Department of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany
227 Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
228 rdf:type schema:Organization
229 grid-institutes:grid.7708.8 schema:alternateName Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
230 schema:name Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
231 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...